Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0

Sofia C. Vaz; Judit A. Adam; Roberto C. Delgado Bolton; Pierre Vera; Wouter van Elmpt; Ken Herrmann; Rodney J. Hicks; Yolande Lievens; Andrea Santos; Heiko Schöder; Bernard Dubray; Dimitris Visvikis; Esther G. C. Troost; Lioe-Fee de Geus-Oei

doi:https://doi.org/10.1007/s00259-021-05624-5

Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0

Sofia C. Vaz, Judit A. Adam, Roberto C. Delgado Bolton, Pierre Vera, Wouter van Elmpt, Ken Herrmann, Rodney J. Hicks, Yolande Lievens, Andrea Santos, Heiko Schöder, Bernard Dubray, Dimitris Visvikis, Esther G. C. Troost, Lioe-Fee de Geus-Oei

Research output: Contribution to journal › Article › Academic › peer-review

22 Citations (Scopus)

Abstract

Purpose: 2-[18F]FDGPET/CT is of utmost importance for radiation treatment (RT) planning and response monitoring in lung cancer patients, in both non-small and small cell lung cancer (NSCLC and SCLC). This topic has been addressed in guidelines composed by experts within the field of radiation oncology. However, up to present, there is no procedural guideline on this subject, with involvement of the nuclear medicine societies. Methods: A literature review was performed, followed by a discussion between a multidisciplinary team of experts in the different fields involved in the RT planning of lung cancer, in order to guide clinical management. The project was led by experts of the two nuclear medicine societies (EANM and SNMMI) and radiation oncology (ESTRO). Results and conclusion: This guideline results from a joint and dynamic collaboration between the relevant disciplines for this topic. It provides a worldwide, state of the art, and multidisciplinary guide to 2-[18F]FDG PET/CT RT planning in NSCLC and SCLC. These practical recommendations describe applicable updates for existing clinical practices, highlight potential flaws, and provide solutions to overcome these as well. Finally, the recent developments considered for future application are also reviewed.

Original language	English
Pages (from-to)	1386-1406
Number of pages	21
Journal	European journal of nuclear medicine and molecular imaging
Volume	49
Issue number	4
Early online date	2022
DOIs	https://doi.org/10.1007/s00259-021-05624-5
Publication status	Published - 1 Mar 2022

Keywords

CT
ESTRO, 2-[ F]FDG PET
ESTRO, 2-[F]FDG PET
Lung cancer
Planning
Radiation therapy
Radiotherapy, EANM
SNMMI

Access to Document

https://doi.org/10.1007/s00259-021-05624-5

Cite this

Vaz, S. C., Adam, J. A., Bolton, R. C. D., Vera, P., van Elmpt, W., Herrmann, K., Hicks, R. J., Lievens, Y., Santos, A., Schöder, H., Dubray, B., Visvikis, D., Troost, E. G. C., & de Geus-Oei, L.-F. (2022). Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0. European journal of nuclear medicine and molecular imaging, 49(4), 1386-1406. https://doi.org/10.1007/s00259-021-05624-5

@article{04751d5da4814da6aa58ff1e149492ee,

title = "Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0",

abstract = "Purpose: 2-[18F]FDGPET/CT is of utmost importance for radiation treatment (RT) planning and response monitoring in lung cancer patients, in both non-small and small cell lung cancer (NSCLC and SCLC). This topic has been addressed in guidelines composed by experts within the field of radiation oncology. However, up to present, there is no procedural guideline on this subject, with involvement of the nuclear medicine societies. Methods: A literature review was performed, followed by a discussion between a multidisciplinary team of experts in the different fields involved in the RT planning of lung cancer, in order to guide clinical management. The project was led by experts of the two nuclear medicine societies (EANM and SNMMI) and radiation oncology (ESTRO). Results and conclusion: This guideline results from a joint and dynamic collaboration between the relevant disciplines for this topic. It provides a worldwide, state of the art, and multidisciplinary guide to 2-[18F]FDG PET/CT RT planning in NSCLC and SCLC. These practical recommendations describe applicable updates for existing clinical practices, highlight potential flaws, and provide solutions to overcome these as well. Finally, the recent developments considered for future application are also reviewed.",

keywords = "CT, ESTRO, 2-[ F]FDG PET, ESTRO, 2-[F]FDG PET, Lung cancer, Planning, Radiation therapy, Radiotherapy, EANM, SNMMI",

author = "Vaz, {Sofia C.} and Adam, {Judit A.} and Bolton, {Roberto C. Delgado} and Pierre Vera and {van Elmpt}, Wouter and Ken Herrmann and Hicks, {Rodney J.} and Yolande Lievens and Andrea Santos and Heiko Sch{\"o}der and Bernard Dubray and Dimitris Visvikis and Troost, {Esther G. C.} and {de Geus-Oei}, Lioe-Fee",

note = "Funding Information: Ken Herrmann reports personal fees from Bayer, personal fees and other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, personal fees from Novartis, personal fees from ymabs, personal fees from Aktis Oncology, personal fees from Theragnostics, and personal fees from Pharma15, outside the submitted work. Funding Information: This guideline was brought to the attention of the relevant EANM Committees and the National Societies of Nuclear Medicine. The comments and suggestions from the EANM Dosimetry and Radiation Protection Committees, the SNMMI, and ESTRO-ACROP were highly appreciated and have been considered for this guideline. Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = mar,

day = "1",

doi = "https://doi.org/10.1007/s00259-021-05624-5",

language = "English",

volume = "49",

pages = "1386--1406",

journal = "European journal of nuclear medicine and molecular imaging",

issn = "1619-7070",

publisher = "Springer Verlag",

number = "4",

}

Vaz, SC, Adam, JA, Bolton, RCD, Vera, P, van Elmpt, W, Herrmann, K, Hicks, RJ, Lievens, Y, Santos, A, Schöder, H, Dubray, B, Visvikis, D, Troost, EGC & de Geus-Oei, L-F 2022, 'Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0', European journal of nuclear medicine and molecular imaging, vol. 49, no. 4, pp. 1386-1406. https://doi.org/10.1007/s00259-021-05624-5

Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0. / Vaz, Sofia C.; Adam, Judit A.; Bolton, Roberto C. Delgado et al.
In: European journal of nuclear medicine and molecular imaging, Vol. 49, No. 4, 01.03.2022, p. 1386-1406.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0

AU - Vaz, Sofia C.

AU - Adam, Judit A.

AU - Bolton, Roberto C. Delgado

AU - Vera, Pierre

AU - van Elmpt, Wouter

AU - Herrmann, Ken

AU - Hicks, Rodney J.

AU - Lievens, Yolande

AU - Santos, Andrea

AU - Schöder, Heiko

AU - Dubray, Bernard

AU - Visvikis, Dimitris

AU - Troost, Esther G. C.

AU - de Geus-Oei, Lioe-Fee

N1 - Funding Information: Ken Herrmann reports personal fees from Bayer, personal fees and other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, personal fees from Novartis, personal fees from ymabs, personal fees from Aktis Oncology, personal fees from Theragnostics, and personal fees from Pharma15, outside the submitted work. Funding Information: This guideline was brought to the attention of the relevant EANM Committees and the National Societies of Nuclear Medicine. The comments and suggestions from the EANM Dosimetry and Radiation Protection Committees, the SNMMI, and ESTRO-ACROP were highly appreciated and have been considered for this guideline. Publisher Copyright: © 2022, The Author(s).

PY - 2022/3/1

Y1 - 2022/3/1

N2 - Purpose: 2-[18F]FDGPET/CT is of utmost importance for radiation treatment (RT) planning and response monitoring in lung cancer patients, in both non-small and small cell lung cancer (NSCLC and SCLC). This topic has been addressed in guidelines composed by experts within the field of radiation oncology. However, up to present, there is no procedural guideline on this subject, with involvement of the nuclear medicine societies. Methods: A literature review was performed, followed by a discussion between a multidisciplinary team of experts in the different fields involved in the RT planning of lung cancer, in order to guide clinical management. The project was led by experts of the two nuclear medicine societies (EANM and SNMMI) and radiation oncology (ESTRO). Results and conclusion: This guideline results from a joint and dynamic collaboration between the relevant disciplines for this topic. It provides a worldwide, state of the art, and multidisciplinary guide to 2-[18F]FDG PET/CT RT planning in NSCLC and SCLC. These practical recommendations describe applicable updates for existing clinical practices, highlight potential flaws, and provide solutions to overcome these as well. Finally, the recent developments considered for future application are also reviewed.

AB - Purpose: 2-[18F]FDGPET/CT is of utmost importance for radiation treatment (RT) planning and response monitoring in lung cancer patients, in both non-small and small cell lung cancer (NSCLC and SCLC). This topic has been addressed in guidelines composed by experts within the field of radiation oncology. However, up to present, there is no procedural guideline on this subject, with involvement of the nuclear medicine societies. Methods: A literature review was performed, followed by a discussion between a multidisciplinary team of experts in the different fields involved in the RT planning of lung cancer, in order to guide clinical management. The project was led by experts of the two nuclear medicine societies (EANM and SNMMI) and radiation oncology (ESTRO). Results and conclusion: This guideline results from a joint and dynamic collaboration between the relevant disciplines for this topic. It provides a worldwide, state of the art, and multidisciplinary guide to 2-[18F]FDG PET/CT RT planning in NSCLC and SCLC. These practical recommendations describe applicable updates for existing clinical practices, highlight potential flaws, and provide solutions to overcome these as well. Finally, the recent developments considered for future application are also reviewed.

KW - CT

KW - ESTRO, 2-[ F]FDG PET

KW - ESTRO, 2-[F]FDG PET

KW - Lung cancer

KW - Planning

KW - Radiation therapy

KW - Radiotherapy, EANM

KW - SNMMI

UR - http://www.scopus.com/inward/record.url?scp=85122802309&partnerID=8YFLogxK

U2 - https://doi.org/10.1007/s00259-021-05624-5

DO - https://doi.org/10.1007/s00259-021-05624-5

M3 - Article

C2 - 35022844

SN - 1619-7070

VL - 49

SP - 1386

EP - 1406

JO - European journal of nuclear medicine and molecular imaging

JF - European journal of nuclear medicine and molecular imaging

IS - 4

ER -

Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0

Abstract

Keywords

Access to Document

Other files and links

Cite this